← All claims

Longevity & Aging

IDO1 inhibition (blocking tryptophan->kynurenine) restores astrocyte glycolysis and rescues memory across amyloid and tau Alzheimer's models

In plain terms: Can blocking an enzyme (IDO1) that both amyloid and tau switch on rescue memory in Alzheimer's models?

Strong support Longevity & Aging 🔬 Includes disconfirming
RefutedContestedStrong support
consensus score 0.76

One strong mouse/cell study (Science 2024) shows amyloid and tau activate astrocytic IDO1->kynurenine, choking brain glucose use, and that blocking IDO1 restores memory; independent data confirm kynurenine pathway disturbance in human AD but the memory-rescue causal claim rests on this single lab.

Evidence ladder

How far up the ladder this claim has climbed. A high consensus on a low rung means "consistent so far," not "proven in people."

Top evidence so far: All trials, pooled (Meta-analysis)

MechanismIn-vitroAnimalObservationalRCTMeta-analysis

How the studies fall

8 support 1 contradict 0 tested null 1 mixed · 10 sources, 7 independent groups

What the evidence shows

<!-- vault-context --> Norwitz **affirms** this claim. Consensus below reflects independent literature only.

The evidence (10)

SourceGradeStanceQualityFinding
Minhas
2024 · Science
animal supports high Cited paper: Abeta & tau activate astrocytic IDO1->KYN, suppressing glycolysis (AhR-dependent); IDO1 inhibition restores hippocampal LTP & memory across AD mouse models + AD-patient cocultures.
Bakker
2023 · Brain Behav Immun
observational mixed moderate Plasma/CSF kynurenines relate variably to AD pathology markers; pathway altered but associations modest/inconsistent.
Cespedes
2022 · Neurobiol Dis
observational supports moderate Systemic kynurenine-pathway perturbations precede progression to dementia independently of amyloid; human cohort, corroborates pathway relevance.
Dos Reis
2025 · Alzheimers Dement
observational supports moderate Independent human data: kynurenine-pathway metabolite alterations in AD and Down-syndrome AD; corroborates pathway, not the intervention.
Souza
2016 · Brain Behav Immun
animal supports moderate IDO inhibitor 1-MT prevented memory and emotional deficits after intracerebroventricular amyloid-beta in mice.
Zhang
2026 · Horm Behav
animal supports moderate In APP/PS1 female mice, IDO1 inhibitor 1-MT reversed cognitive impairment and normalized Trp/Kyn metabolism.
Qian
2021 · Theranostics
animal contradicts moderate Directional wrinkle: AhR ACTIVATION (not inhibition) rescues AD-mouse cognition via neprilysin; complicates the IDO1->KYN->AhR-as-harmful framing.
Almulla
2022 · J Alzheimers Dis
meta-analysis supports moderate Meta-analysis: kynurenine/TRYCAT pathway is dysregulated in AD; supports the upstream premise (KYN disturbance) but not the IDO1-inhibition memory rescue.
Souza
2017 · Behav Brain Res
animal supports low Swimming exercise reduced IDO/kynurenine activation and improved amyloid-beta-induced behavioral disturbances in mice, implicating IDO1 in cognitive impairment.
Minhas
2024 · bioRxiv
animal supports moderate Preprint of the Science study showing IDO1 inhibition restores hippocampal glucose metabolism and rescues memory across amyloid and tau models.

Disagree, or know a study we missed?

We grade by evidence, not opinions. The way to weigh in is to point us to a study we haven't cited (check the evidence table above first), or to flag a problem with one we have. Every submission is reviewed; if it holds up, the grade updates and shows in Science Changes Its Mind.

📚 Suggest a study ⚑ Flag / request reclassification

Opens a short form. You'll sign in with Google so submissions are tied to a real account — we don't display your identity, and we only accept a link we can verify (PubMed, DOI, ClinicalTrials.gov).

Educational only, not medical advice. Grades and scores reflect published evidence weighted by study design and quality; see the methodology.